Projections of anxiety disorder prevalence during and beyond the COVID-19 pandemic in Germany using the illness-death model.

Projections of anxiety disorder prevalence during and beyond the COVID-19 pandemic in Germany using the illness-death model.

Publication date: Oct 10, 2024

Although there is now substantial evidence on the acute impacts of the COVID-19 pandemic on anxiety disorders, the long-term population impact of the pandemic remains largely unexplored. To quantify a possible longitudinal population-level impact of the pandemic by projecting the prevalence of anxiety disorders through 2030 among men and women aged up to 95 years in Germany under scenarios with varying impacts of the pandemic on the incidence of anxiety disorders. We used a three-state illness-death model and data from the Global Burden of Disease Study to model historical trends of the prevalence and incidence of anxiety disorders. The German population projections determined the initial values for projections. The COVID-19 incidence rate data informed an additional incidence model, which was parameterised with a wash-in period, delay, wash-out period, incidence increase level and decay constant. When no additional increase in the incidence during the pandemic waves during 2020-2022 was assumed, it was estimated that 3. 86 million women (9. 96%) and 2. 13 million men (5. 40%) would have anxiety disorders in 2030. When increases in incidence following pandemic waves were assumed, the most extreme scenario projected 5. 67 million (14. 02%) women and 3. 30 million (8. 14%) men with the mental disorder in 2030. Any increased incidence during the pandemic resulted in elevated prevalence over the projection period. Projection of anxiety disorder prevalence based on the illness-death model enables simulations with varying assumptions and provides insight for public health planning. These findings should be refined as trend data accumulate and become available.

Open Access PDF

Concepts Keywords
Bjpsych Anxiety disorders
Germany COVID-19
Pandemic epidemiology
Unexplored incidence
prevalence

Semantics

Type Source Name
disease MESH anxiety disorder
disease MESH COVID-19 pandemic
disease MESH death
disease MESH mental disorder
pathway REACTOME Reproduction
disease MESH anxiety
disease MESH phobias
disease MESH panic disorder
disease MESH social anxiety disorder
disease MESH sequelae
disease MESH depression
disease MESH emergency
disease IDO country
disease MESH chronic diseases
disease MESH comorbidity
disease MESH uncertainty
drug DRUGBANK Ranitidine
drug DRUGBANK Coenzyme M
drug DRUGBANK Pentaerythritol tetranitrate

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *